SA News • Fri, Oct. 31
From other sites
GlycoMimetics: A Promising Sickle Cell Disease Play
- GlycoMimetics’ GMI-1070 is a first-in-class pan-selectin inhibitor that could shorten sickle cell disease vaso-occlusive crisis, and has the potential for more than 1 billion peak sales.
- Strong Phase 2 GMI-1070 data showed consistent improvements in the duration of crisis, use of opiods, and other clinical metrics, which bodes well for Phase 3 chance of success.
- While early, GlycoMimetics’ GMI-1271 for the treatment of AML could drive GLYC shares meaningfully higher.
There are no Transcripts on GLYC.
Fri, Oct. 31, 11:41 AM
Thu, Jul. 31, 6:34 PM
Thu, Jul. 31, 5:23 PM
Thu, May. 8, 10:02 AM
Mon, Mar. 31, 9:23 AM
GLYC vs. ETF Alternatives
GlycoMimetics Inc is a clinical stage biotechnology company. The Company is engaged in discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role.
Other News & PR